RxDoctor Payments Data

Bozena Bitner, MD

Internal Medicine · North Arlington, NJNPI 1609878438

Payments from drug & device makers

$12,640in general payments, 2019–2025

Across 654 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$2K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$12,587100%
  • Education$530%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,640 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$60,323
Medicare patients
144
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide191$249,378
JardianceEmpagliflozin99$125,232
FarxigaDapagliflozin Propanediol50$65,563
OzempicSemaglutide43$60,246
ProliaDenosumab26$45,972
RybelsusSemaglutide26$38,098
LinzessLinaclotide21$23,925
EntrestoSacubitril/Valsartan16$22,906
TrulicityDulaglutide14$22,515
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$21,563
VascepaIcosapent Ethyl23$19,155
TradjentaLinagliptin16$17,447
EliquisApixaban12$16,979
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,057
JanuviaSitagliptin Phosphate18$13,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,554$271,893205 claims
Boehringer IngelheimJardiance, Tradjenta$1,127$142,680115 claims
Novo NordiskOzempic, Rybelsus$1,348$98,34569 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,955$87,12675 claims
AmgenProlia$1,223$45,97226 claims
AbbVieLinzess, Synthroid$1,273$27,97263 claims
PfizerEliquis, Abrysvo$234$21,01028 claims
MerckJanuvia, Steglatro$290$18,05331 claims
GSKTrelegy Ellipta$354$16,05719 claims
Sanofi-aventis U.S. LLCAdmelog$162$1,28711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in North Arlington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →